(Reuters) -Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 ...

The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.

China on Sunday announced anti-dumping duties as high as 74.9% on imports of POM copolymers, a type of engineering plastic, ...

In its Friday approval letter, the FDA didn’t explain the restrictions although they reflect skepticism about ...

Novavax, Inc. (Nasdaq: NVAX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics ...

The FDA has approved the Novavax Covid-19 vaccine, but with restrictions, limiting its use to older adults and those over 12 ...

Gaithersburg’s Novavax has secured formal regulatory approval for its Covid vaccine. It's a major win, after the FDA delayed ...

Investors reacted positively to the news, as the FDA’s approval not only enhances Novavax’s product offering but also solidifies its partnership with Sanofi, a key player in the vaccine market. The ...

After a prolonged wait, American company Novavax (Nasdaq: NVAX) has received full approval from the US regulator for its ...

The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s COVID-19 vaccine, restricting its use to ...

This vaccine did previously have emergency approval by the FDA for use but can now be marketed in the U.S. for use, the ...